Keywords: Eli Lilly, Insulin production, Sanofi, Lemtrada pricing, The Lancet, Multiple sclerosis
News briefs: Eli Lilly expands insulin facility; and Sanofi criticized over Lemtrada
Article | 02 November 2012
US drug major Eli Lilly (NYSE: LLY) has announced a $140 million expansion to the company's Indianapolis insulin manufacturing operations. The 80,000 ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
